PSORIASIS AND CARDIOVASCULAR DISEASE: IMMUNOMODULATOR ROLE OF THE TREATMENT WITH ROSUVASTATIN IN PATIENTS WITH PSORIASIS OF MILD OR OF MODERATE-SEVERE SKIN DISEASE. - ND

POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI0 个研究点开始时间: 2009年7月29日最近更新: 2014年2月10日

试验速览

暂无简介。

•The following inclusion criteria will have to be met:
•1.age >18 years
•2.active but clinically stable plaque psoriasis
•3.involvement of at least 10 percent of the body surface area for the moderate-severe group and < 10% for the group with mild psoriasi
•4.minimal psoriasis area-and-severity index of <10 or >10 for the two groups respectively during the screening period
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•The following criteria will preclude participation to the study:
•1.pregnancy and nursing
•2.guttate, erythrodernic, or pustular psoriasis at the time of screening
•3.previous treatment with etanercept or anti-TNF antibodies
•4.previous treatment with anti-CD4 antibodies or interleukin-2-diphtheria-toxin fusion protein within the previous six months
•5.previous treatment with biologic or investigational drug, psoralen-ultaviolet A phototherapy, systemic corticosteroids, or systemic psoriasis therapy within the previous four weeks
•6.previous treatment with ultraviolet B phototherapy, topical corticosteroids, vitamin A or D analogues, or anthralin within the previous two weeks antibiotic treatment within the previous week
•7.other inflammatory, tumoral, systemic or skin disease
•8.recent vaccination
•9.previous or current use of lipid-lowering therapy
•10. current use of post menopausal hormone replacement therapy
•11.evidence of hepatic disfunction (alanine amino transferase levels> twice the upper limits of the normal range)
•12.a CK level more than three times the upper limits of the normal range
•13.a Creatinine level higher than 2 mg/dl
•14. a recent history of alcohol or drug abuse.

发起方

POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI